The promises and challenges of early non‐small cell lung cancer detection: patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers

Kalinke, Lukas; Thakrar, Ricky; Janes, Sam M.

doi:10.1002/1878-0261.12864

Cited by 18 publications

(13 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discovery and validation of biomarkers calls for the implementation of a worldwide network of research centers with constant data sharing and dissemination of results. Such connections could focus on those biomarkers that are more appropriate for clinical use [42].…”

Section: Future Perspectivesmentioning

confidence: 99%

Urinary Biomarkers for Early Diagnosis of Lung Cancer

Gasparri

Sedda

Caminiti

et al. 2021

JCM

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths worldwide. Its early detection has the potential to significantly impact the burden of the disease. The screening and diagnostic techniques in current use suffer from limited specificity. The need therefore arises for a reliable biomarker to identify the disease earlier, which can be integrated into a test. This test would also allow for the recurrence risk after surgery to be stratified. In this context, urine could represent a non-invasive alternative matrix, with the urinary metabolomic profile offering a potential source for the discovery of diagnostic biomarkers. This paper aims to examine the current state of research and the potential for translation into clinical practice.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Urinary Biomarkers for Early Diagnosis of Lung Cancer

Gasparri

Sedda

Caminiti

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…12 An alternative would be a method which was more accessible and acceptable to more people in the target group. 13 14 Targeting risk using phenotypic data in electronic medical records and polygenic risk models are options being explored. 15 16 Biomarkers may be suitable but none of the candidates have been shown to be effective so far.…”

Section: Mainmentioning

confidence: 99%

Targeted screening for lung cancer with autoantibodies

Sullivan

Mair

Anderson

et al. 2021

Preprint

View full text Add to dashboard Cite

Earlier detection of lung cancer is possible, but difficult and costly to achieve. Screening with Low Dose Computed Tomography (LDCT)scanning has been shown to reduce mortality by 20-25% over the past decade but uptake amongst those most likely to suffer the disease has been slow. Resource constraints and a high false positive rate have also limited adoption of LDCT in many health systems. Targeted screening of people most likely to benefit using a range of biomarkers may be one way to improve the yield and reduce the resource requirements of LDCT. Autoantibodies, which amplify the signal produced by cancer derived proteins, are present in the blood of people mounting an immune response to cancer are a potential way to select those at highest risk. We have followed up 12 208 people enrolled in the ECLS trial for three years and shown that the specificity for early stage (I &II) disease is 90.3% throughout that period. More cancers were detected in the control than the intervention arm of the trial (101V 83). Sensitivity was 77.8% after 6 months and dropped to 46.4% after 3 years. At the end of three years the hazard ratios (95%CI) for All Cause, Cancer Specific and Lung Cancer Mortality was 0.82(0.67-1.01), 0.72(0.54-0.97) and 0.70(0.46-1.08) respectively for those randomised to Early CDT testing. As a range of treatment modalities become increasingly more effective it is even more important to target LDCT on those most likely to have early stage disease. Autoantibody testing may be one method of targeting early detection on those most likely to benefit.

show abstract

“…), nucleic acids (DNA, RNA), cells (TAMs), and volatile organic compounds (aldehydes) [51,[59][60][61][62][63][64][65]. The detection of biomarker allows for serial sampling by a non-invasive way, but unsatisfactory specificity ascribe the vast inter-tumor heterogeneity [66,67]. The use of nanoparticles can enhance the sensitivity and specificity prominently (Table 1).…”

Section: In Vitro Detectionmentioning

confidence: 99%

Recent Progress of Lung Cancer Diagnosis Using Nanomaterials

et al. 2020

View full text Add to dashboard Cite

Lung cancer is one of the serious malignant tumors with high morbidity and mortality due to the poor diagnosis and early metastasis. The developing nanotechnology provides novel concepts and research strategies for the lung cancer diagnosis by employing nanomaterials as diagnostic reagents to enhance diagnostic efficiency. This commentary introduces recent progress using nanoparticles for lung cancer diagnosis from two aspects of in vivo and in vitro detection. The challenges and future research perspectives are proposed at the end of the paper.

show abstract

The promises and challenges of early non‐small cell lung cancer detection: patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers

Abstract: Article type : Review The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers

Cited by 18 publications

References 186 publications

Urinary Biomarkers for Early Diagnosis of Lung Cancer

Urinary Biomarkers for Early Diagnosis of Lung Cancer

Targeted screening for lung cancer with autoantibodies

Recent Progress of Lung Cancer Diagnosis Using Nanomaterials

Contact Info

Product

Resources

About